Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Bayer CEO: overhaul is leading to pharma pipeline boost

Published by Global Banking and Finance Review

Posted on September 22, 2025

Featured image for article about Headlines

SAN SEBASTIAN (Reuters) -Bayer Chief Executive Bill Anderson said the company is making "remarkable progress" in overcoming longstanding challenges, including a weak drug development pipeline, after an internal management overhaul.

Speaking at a press event in San Sebastian, Spain, Anderson said Bayer had fundamentally redesigned itself and was on track to overcome years of crisis, though a "long way to go" was still ahead.

At the briefing, drug unit head Stefan Oelrich said sales of cancer drug Nubeqa and kidney treatment Kerendia were strong, and heart drug Beyonttra, also known as acoramidis, was now seen as generating more than $1 billion in its peak sales year.

Overall, the sales loss from the expiry of patents for established stroke prevention pill Xarelto and for an older version of eye drug Eylea should be offset by newer products, he added.

Bayer said separately it has started the third phase of human testing of an experimental stem cell therapy for Parkinson's disease, to support longer-term growth ambitions.

CEO Anderson reaffirmed Bayer's goal to make meaningful progress on resolving approximately 61,000 outstanding glyphosate cases by the end of 2026, where plaintiffs claim a cancer-causing effect of the weedkiller.

Anderson also said U.S. tariffs on imports were not a major topic for the group because of its global manufacturing footprint.

(Reporting by Patricia Weiss, writing by Kirsti KnolleEditing by Ludwig Burger)